{"id":109949,"date":"2026-08-24T14:43:21","date_gmt":"2026-08-24T14:43:21","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/109949\/"},"modified":"2026-08-24T14:43:21","modified_gmt":"2026-08-24T14:43:21","slug":"gsk-shares-kept-at-neutral-by-citi-as-unproven-phase-iii-pipeline-curbs-long-term-growth","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/109949\/","title":{"rendered":"GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth"},"content":{"rendered":"

\"GSK<\/a> GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth Proactive uses images sourced from Shutterstock <\/p>\n

GSK PLC (LSE:GSK, NYSE:GSK)<\/a>\u00a0got a grudging nod from Citi on Thursday, as the investment bank lifted its earnings forecasts for the drugmaker but stopped well short of a buy call. <\/p>\n

The shares edged up 0.31% to 1,922p as Citi kept its ‘neutral’ rating, tweaking its model after GSK’s Accelerate Growth event and second-quarter results. <\/p>\n

At the heart of the update is a \u00a31.9 billion cost-savings drive being funnelled straight back into research and development. <\/p>\n

That cash is helping bankroll 20 phase III trials due to launch in 2026, of which Citi has so far written 12 into its numbers. <\/p>\n

Those trials, plus the broader economies, should nudge earnings per share 1% to 4% higher between 2027 and 2030. <\/p>\n

Some of the savings are also expected to cushion margins when HIV drug dolutegravir loses exclusivity late this decade. <\/p>\n

In the same note, Citi flagged that external data on many of the coming trials is still thin, leaving its forecasts on shaky foundations. <\/p>\n

Its projected 2% compound annual earnings growth remains the feeblest in the European pharma pack. <\/p>\n

Management, the bank warned, must sharpen its execution to win the market round on growth beyond 2031. <\/p>\n

Hanging over it all is the Jemperli litigation with AnaptysBio, with a post-trial hearing set for 20 October and a ruling expected by early 2027. <\/p>\n","protected":false},"excerpt":{"rendered":"GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth Proactive uses images…\n","protected":false},"author":2,"featured_media":109950,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[45429,13099,273,20785,21214,1831,37362],"class_list":["post-109949","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-accelerate-growth","tag-citi","tag-earnings-growth","tag-gsk","tag-gsk-plc","tag-gsk-shares","tag-phase-iii-trials"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117151020001376723","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/109949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=109949"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/109949\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/109950"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=109949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=109949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=109949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}